Data Sheet (Cat.No.T27677)

TargetMol

JNJ-37822681

Chemical Properties



CAS No. : 935776-74-2

Formula: C17H17F5N4

Molecular Weight: 372.34

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	JNJ-37822681 is a novel, highly selective dopamine D_2 receptor antagonist characterized by a rapid dissociation rate from the dopamine D_2 receptor.
Targets(IC50)	Dopamine Receptor
In vivo	JNJ-37822681 occupied D2 receptors in rat brain at relatively low doses (ED50 = 0.39 mg/kg) and was effective in animal models of psychosis (e.g., inhibition of apomorphine-induced stereotypy or D-amphetamine/phencyclidine-induced hyperlocomotion)[4].

Solubility Information

Solubility	DMSO: 55 mg/mL (147.71 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.6857 mL	13.4286 mL	26.8572 mL
5 mM	0.5371 mL	2.6857 mL	5.3714 mL
10 mM	0.2686 mL	1.3429 mL	2.6857 mL
50 mM	0.0537 mL	0.2686 mL	0.5371 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Langlois X, et al. Pharmacology of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia. J Pharmacol Exp Ther. 2012 Jul;342(1):91-105.
de Waal EJ,et al. Differential responses to JNJ-37822681, a specific and fast dissociating dopamine D2 receptor antagonist, in cynomolgus monkey and Sprague-Dawley rat general toxicology studies: clinical observations, prolactin levels, mammary histopathology findings and toxicokinetics. J Appl Toxicol. 2014 Sep;34(9):974-92.
Daly EJ, et al. Metabolic and body mass parameters after treatment with JNJ-37822681, a novel fast-dissociating D2 receptor antagonist, vs olanzapine in patients with schizophrenia. Ann Clin Psychiatry. 2013 Aug;25(3):173-83.
Hoeben E, et al. Population pharmacokinetics of JNJ-37822681, a selective fast-dissociating dopamine D_2-receptor antagonist, in healthy subjects and subjects with schizophrenia and dose selection based on simulated D_2-receptor occupancy. Clin Pharmacokinet. 2013 Nov;52(11):1005-15.

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481